Close menu


Press release

Poxel Announces Positive Histology Results from Phase 2 NASH Trial (DESTINY-1) for PXL065, a Novel, Proprietary Deuterium-Stabilized Rstereoisomer of Pioglitazone


  • PXL065 Phase 2 trial for the treatment of NASH met its primary efficacy endpoint for liver fat content reduction at 36-weeks for all doses.
  • Histology findings from paired liver biopsies showed strong improvement in fibrosis without worsening of NASH, consistent with dose dependent reduction of all biomarkers related to fibrogenesis and fibrosis risk scores; improvement seen in other NASH histology components.
  • Additional benefits on glucose control (HbA1c) and multiple indices of insulin sensitivity.
  • Validation of PXL065 hypothesis – combining efficacy on liver and metabolic endpoints with reduced potential for PPARγ side effects (weight gain and edema).
  • Investor webcast today to further discuss data


Read the press release


More information